Metabolomics and network analysis uncovered profound inflammation-associated alterations in hepatitis B virus-related cirrhosis patients with early hepatocellular carcinoma
Patients with hepatitis B virus (HBV)-related liver cirrhosis (LC) are at high risk for hepatocellular carcinoma (HCC). Limitations in the early detection of HCC give rise to poor survival in this high-risk population. Here, we performed comprehensive metabolomics on health individuals and HBV-relat...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2023-05-01
|
| Series: | Heliyon |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2405844023032905 |
| _version_ | 1827937371728904192 |
|---|---|
| author | Zhiyong Du Shengju Yin Bing Liu Wenxin Zhang Jiaxu Sun Meng Fang Yisheng Xu Kun Hua Pengfei Tu Guoliang Zhang Ying Ma Yingyuan Lu |
| author_facet | Zhiyong Du Shengju Yin Bing Liu Wenxin Zhang Jiaxu Sun Meng Fang Yisheng Xu Kun Hua Pengfei Tu Guoliang Zhang Ying Ma Yingyuan Lu |
| author_sort | Zhiyong Du |
| collection | DOAJ |
| description | Patients with hepatitis B virus (HBV)-related liver cirrhosis (LC) are at high risk for hepatocellular carcinoma (HCC). Limitations in the early detection of HCC give rise to poor survival in this high-risk population. Here, we performed comprehensive metabolomics on health individuals and HBV-related LC patients with and without early HCC. Compared to non-HCC patients (N = 108) and health controls (N = 80), we found that patients with early HCC (N = 224) exhibited a specific plasma metabolome map dominated by lipid alterations, including lysophosphatidylcholines, lysophosphatidic acids and bile acids. Pathway and function network analyses indicated that these metabolite alterations were closely associated with inflammation responses. Using multivariate regression and machine learning approaches, we identified a five-metabolite combination that showed significant performances in differentiating early-HCC from non-HCC than α-fetoprotein (area under the curve values, 0.981 versus 0.613). At metabolomic levels, this work provides additional insights of metabolic dysfunction related to HCC progressions and demonstrates the plasma metabolites might be measured to identify early HCC in patients with HBV-related LC. |
| first_indexed | 2024-03-13T08:24:40Z |
| format | Article |
| id | doaj.art-3d6e87f5c1d349a7bf301bbc4e63ee79 |
| institution | Directory Open Access Journal |
| issn | 2405-8440 |
| language | English |
| last_indexed | 2024-03-13T08:24:40Z |
| publishDate | 2023-05-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Heliyon |
| spelling | doaj.art-3d6e87f5c1d349a7bf301bbc4e63ee792023-05-31T04:46:34ZengElsevierHeliyon2405-84402023-05-0195e16083Metabolomics and network analysis uncovered profound inflammation-associated alterations in hepatitis B virus-related cirrhosis patients with early hepatocellular carcinomaZhiyong Du0Shengju Yin1Bing Liu2Wenxin Zhang3Jiaxu Sun4Meng Fang5Yisheng Xu6Kun Hua7Pengfei Tu8Guoliang Zhang9Ying Ma10Yingyuan Lu11Beijing Anzhen Hospital, Capital Medical University, Beijing Institute of Heart Lung and Blood Vessel Disease, Beijing, 100029, ChinaState Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing, 100191, China; Shanghai Key Laboratory of Children's Environment Health, School of Public Health/Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China; Shandong Jiaotong Hospital, Jinan, 250031, ChinaState Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing, 100191, ChinaState Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing, 100191, ChinaState Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing, 100191, ChinaState Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing, 100191, ChinaWaters Technologies Ltd., Beijing, 102600, ChinaBeijing Anzhen Hospital, Capital Medical University, Beijing Institute of Heart Lung and Blood Vessel Disease, Beijing, 100029, ChinaState Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing, 100191, ChinaSchool of Basic Medical Sciences, Peking University, Beijing, 100191, China; Corresponding author.State Key Laboratory Breeding Base of Dao-di Herbs, National Resource Center for Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing, 100700, China; Corresponding author.State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing, 100191, China; Corresponding author.Patients with hepatitis B virus (HBV)-related liver cirrhosis (LC) are at high risk for hepatocellular carcinoma (HCC). Limitations in the early detection of HCC give rise to poor survival in this high-risk population. Here, we performed comprehensive metabolomics on health individuals and HBV-related LC patients with and without early HCC. Compared to non-HCC patients (N = 108) and health controls (N = 80), we found that patients with early HCC (N = 224) exhibited a specific plasma metabolome map dominated by lipid alterations, including lysophosphatidylcholines, lysophosphatidic acids and bile acids. Pathway and function network analyses indicated that these metabolite alterations were closely associated with inflammation responses. Using multivariate regression and machine learning approaches, we identified a five-metabolite combination that showed significant performances in differentiating early-HCC from non-HCC than α-fetoprotein (area under the curve values, 0.981 versus 0.613). At metabolomic levels, this work provides additional insights of metabolic dysfunction related to HCC progressions and demonstrates the plasma metabolites might be measured to identify early HCC in patients with HBV-related LC.http://www.sciencedirect.com/science/article/pii/S2405844023032905Hepatocellular carcinomaLiver cirrhosisHepatitis B virusMetabolomics |
| spellingShingle | Zhiyong Du Shengju Yin Bing Liu Wenxin Zhang Jiaxu Sun Meng Fang Yisheng Xu Kun Hua Pengfei Tu Guoliang Zhang Ying Ma Yingyuan Lu Metabolomics and network analysis uncovered profound inflammation-associated alterations in hepatitis B virus-related cirrhosis patients with early hepatocellular carcinoma Heliyon Hepatocellular carcinoma Liver cirrhosis Hepatitis B virus Metabolomics |
| title | Metabolomics and network analysis uncovered profound inflammation-associated alterations in hepatitis B virus-related cirrhosis patients with early hepatocellular carcinoma |
| title_full | Metabolomics and network analysis uncovered profound inflammation-associated alterations in hepatitis B virus-related cirrhosis patients with early hepatocellular carcinoma |
| title_fullStr | Metabolomics and network analysis uncovered profound inflammation-associated alterations in hepatitis B virus-related cirrhosis patients with early hepatocellular carcinoma |
| title_full_unstemmed | Metabolomics and network analysis uncovered profound inflammation-associated alterations in hepatitis B virus-related cirrhosis patients with early hepatocellular carcinoma |
| title_short | Metabolomics and network analysis uncovered profound inflammation-associated alterations in hepatitis B virus-related cirrhosis patients with early hepatocellular carcinoma |
| title_sort | metabolomics and network analysis uncovered profound inflammation associated alterations in hepatitis b virus related cirrhosis patients with early hepatocellular carcinoma |
| topic | Hepatocellular carcinoma Liver cirrhosis Hepatitis B virus Metabolomics |
| url | http://www.sciencedirect.com/science/article/pii/S2405844023032905 |
| work_keys_str_mv | AT zhiyongdu metabolomicsandnetworkanalysisuncoveredprofoundinflammationassociatedalterationsinhepatitisbvirusrelatedcirrhosispatientswithearlyhepatocellularcarcinoma AT shengjuyin metabolomicsandnetworkanalysisuncoveredprofoundinflammationassociatedalterationsinhepatitisbvirusrelatedcirrhosispatientswithearlyhepatocellularcarcinoma AT bingliu metabolomicsandnetworkanalysisuncoveredprofoundinflammationassociatedalterationsinhepatitisbvirusrelatedcirrhosispatientswithearlyhepatocellularcarcinoma AT wenxinzhang metabolomicsandnetworkanalysisuncoveredprofoundinflammationassociatedalterationsinhepatitisbvirusrelatedcirrhosispatientswithearlyhepatocellularcarcinoma AT jiaxusun metabolomicsandnetworkanalysisuncoveredprofoundinflammationassociatedalterationsinhepatitisbvirusrelatedcirrhosispatientswithearlyhepatocellularcarcinoma AT mengfang metabolomicsandnetworkanalysisuncoveredprofoundinflammationassociatedalterationsinhepatitisbvirusrelatedcirrhosispatientswithearlyhepatocellularcarcinoma AT yishengxu metabolomicsandnetworkanalysisuncoveredprofoundinflammationassociatedalterationsinhepatitisbvirusrelatedcirrhosispatientswithearlyhepatocellularcarcinoma AT kunhua metabolomicsandnetworkanalysisuncoveredprofoundinflammationassociatedalterationsinhepatitisbvirusrelatedcirrhosispatientswithearlyhepatocellularcarcinoma AT pengfeitu metabolomicsandnetworkanalysisuncoveredprofoundinflammationassociatedalterationsinhepatitisbvirusrelatedcirrhosispatientswithearlyhepatocellularcarcinoma AT guoliangzhang metabolomicsandnetworkanalysisuncoveredprofoundinflammationassociatedalterationsinhepatitisbvirusrelatedcirrhosispatientswithearlyhepatocellularcarcinoma AT yingma metabolomicsandnetworkanalysisuncoveredprofoundinflammationassociatedalterationsinhepatitisbvirusrelatedcirrhosispatientswithearlyhepatocellularcarcinoma AT yingyuanlu metabolomicsandnetworkanalysisuncoveredprofoundinflammationassociatedalterationsinhepatitisbvirusrelatedcirrhosispatientswithearlyhepatocellularcarcinoma |